Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI110 plus sintilimab in advanced alveolar soft part sarcoma
ChiCTR2500097943Phase 2Completed
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ibi110 and sintilimab in alveolar soft part sarcoma (ASPS) (2 cohorts), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Started Feb 2025; status: completed.
02
Drugs
ibi110sintilimab
03
Conditions
alveolar soft part sarcoma (ASPS)
Beyond the preview
Go deeper on ChiCTR2500097943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097943.